NLS Pharmaceutics
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Employees
- 4
- Market Cap
- -
- Website
- http://www.nlspharma.com
- Introduction
NLS Pharmaceutics AG engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders. These disorders include narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as ADHD. The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
- Conditions
- Narcolepsy Type 1Narcolepsy With Cataplexy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- NLS Pharmaceutics
- Target Recruit Count
- 48
- Registration Number
- NCT05914194
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
- Conditions
- NarcolepsyNarcolepsy With CataplexyNarcolepsy Without Cataplexy
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- NLS Pharmaceutics
- Target Recruit Count
- 52
- Registration Number
- NCT05055024
- Locations
- ๐บ๐ธ
NeuroTrials Research, Atlanta, Georgia, United States
๐บ๐ธStanford Sleep Medicine Center, Redwood City, California, United States
๐บ๐ธSt. Francis Sleep Allergy and Lung Institute, Clearwater, Florida, United States
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
- Conditions
- Excessive Daytime SleepinessNarcolepsyCataplexy Narcolepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- NLS Pharmaceutics
- Target Recruit Count
- 67
- Registration Number
- NCT04923594
- Locations
- ๐บ๐ธ
Clinical Research Institute, Stockbridge, Georgia, United States
๐บ๐ธCarolinas Sleep Specialists, Concord, North Carolina, United States
๐บ๐ธSuperior Clinical Research, LLC, Goldsboro, North Carolina, United States
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- NLS Pharmaceutics
- Target Recruit Count
- 84
- Registration Number
- NCT02808104
- Locations
- ๐บ๐ธ
AVIDA Clinic, Newport Beach, California, United States
๐บ๐ธCNS Healthcare, Jacksonville, Florida, United States
๐บ๐ธMidwest Research Group / St. Charles Psychiatric Associates, St. Charles, Missouri, United States